Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

People with COPD are vulnerable to small increases in PM2.5, with each 1 μg/m3 rise in long-term exposure linked to a 3.8% ...

Researchers warn of increased cannabis use among older US adults, as experts link it to health risks and complications in ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

For the many who first saw Edward Scissorhands in their youth, and for which it served as a gateway drug into the mind of Tim ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).